Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934786 | 1.00 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| Piperazine SCHEMBL28199664 | 1.00 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| SCHEMBL29832951 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| SCHEMBL5550813 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| SCHEMBL29604422 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| SCHEMBL337070 | 0.98 | HSD17B10 (0.52) | CHRM5CHRM3HSD17B10SIGMAR1CA2 | |
| SCHEMBL62990 | 0.98 | HSD17B10 (0.52) | CHRM5CHRM3HSD17B10SIGMAR1CA2 | |
| SCHEMBL5556374 | 0.96 | CHRM5 (0.47) | CHRM5CHRM3HSD17B10SIGMAR1CXCR4 | |
| Hydrochloric Acid SCHEMBL1373260 | 0.95 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1CA2 | |
| SCHEMBL472213 | 0.95 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117460528-A | anti-CLDN 18.2 antibody conjugates | 苏州创胜医药集团有限公司 | 2024-01-26 | — | — | CN | claimed |
| US-12377177-B2 | Radionuclide labeled polypeptide conjugates and uses thereof | TIANJIN CONJUSTAR BIOLOGICS CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| EP-4531932-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Universiteit Antwerpen (BE) | 2025-04-09 | — | — | EP | disclosed |
| CN-119060140-A | Annular TMTP1 polypeptide ligand radioactive probe and preparation method and application thereof | 厦门大学附属第一医院(厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所) | 2024-12-03 | — | — | CN | disclosed |
| US-20240366811-A1 | RADIONUCLIDE LABELED POLYPEPTIDE CONJUGATES AND USES THEREOF | TIANJIN CONJUSTAR BIOLOGICS CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| WO-2024222840-A1 | NOVEL RADIONUCLIDE-LABELED POLYPEPTIDE CONJUGATE AND USE THEREOF | 天津星联肽生物科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| CN-118045209-A | Positron emission computed tomography molecular imaging probe for targeting protein-lost enteropathy and preparation method and application thereof | 北京市肿瘤防治研究所 | 2024-05-17 | — | — | CN | disclosed |
| CN-117460528-A | anti-CLDN 18.2 antibody conjugates | 苏州创胜医药集团有限公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2023233023-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | UNIVERSITEIT ANTWERPEN (BE) | 2023-12-07 | — | — | WO | disclosed |
| CN-117164664-A | D-type amino acid modified TMTP1 polypeptide ligand radioactive probe and preparation method and application thereof | 厦门大学附属第一医院(厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所) | 2023-12-05 | — | — | CN | disclosed |
| US-20090143529-A1 | Peptide purification by means of hard metal ion affinity chromatography | HEARN MILTON THOMAS WILLIAM | 2009-06-04 | — | — | US | disclosed |
| EP-1758677-A2 | PEPTIDE PURIFICATION BY MEANS OF HARD METAL ION AFFINITY CHROMATOGRAPHY | NOVO NORDISK A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005120700-A2 | PEPTIDE PURIFICATION BY MEANS OF HARD METAL ION AFFINITY CHROMATOGRAPHY | NOVO NORDISK A/S (DK) | 2005-12-22 | — | — | WO | disclosed |
| US-5565562-A | Triaza macrocycles | CELLTECH THERAPEUTICS LIMITED (GB) | 1996-10-15 | — | — | US | disclosed |
| US-5428155-A | PH controlled sulfomethylation of 1,4,7,10-tetraazacyclododecane; displacement with sodium cyanide; hydrolysis to symmetrical acetic acid side groups | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0618910-A1 | SYNTHESIS OF POLYAZAMACROCYCLES WITH MORE THAN ONE TYPE OF SIDE-CHAIN CHELATING GROUPS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-10-12 | — | — | EP | disclosed |
| US-5316757-A | MRI contrast agent | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-05-31 | — | — | US | disclosed |
| WO-1993012097-A1 | SYNTHESIS OF POLYAZAMACROCYCLES WITH MORE THAN ONE TYPE OF SIDE-CHAIN CHELATING GROUPS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-06-24 | — | — | WO | disclosed |
| WO-1990009379-A1 | AZA-MACROCYCLES AND PROCESSES FOR THEIR PREPARATION | CELLTECH LIMITED (GB) | 1990-08-23 | — | — | WO | disclosed |
| EP-0382583-A1 | Aza macrocycles and processes for their preparation | CELLTECH THERAPEUTICS LIMITED (GB) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366811-A1 | RADIONUCLIDE LABELED POLYPEPTIDE CONJUGATES AND USES THEREOF | GRPR, SSTR4, DNPEP | CHRM5 4595/4885CHRM3 4323/4885HSD17B10 3513/4885 |
| US-20090143529-A1 | Peptide purification by means of hard metal ion affinity chromatography | MAX, PTMS, SLC7A1 | CHRM5 4285/4885CHRM3 3842/4885HSD17B10 4794/4885 |
| US-12377177-B2 | Radionuclide labeled polypeptide conjugates and uses thereof | GRPR, SSTR4, DNPEP | CHRM5 4595/4885CHRM3 4323/4885HSD17B10 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.